Today’s Shorts Alert: Can SPOTLIGHT INNOVATION (OTCMKTS:STLT)’s Tomorrow be Different? The Stock Had Increase in Shorts

November 16, 2016 - By Peter Erickson   ·   0 Comments

Today's Shorts Alert: Can SPOTLIGHT INNOVATION (OTCMKTS:STLT)’s Tomorrow be Different? The Stock Had Increase in Shorts

The stock of SPOTLIGHT INNOVATION (OTCMKTS:STLT) registered an increase of 23.08% in short interest. STLT’s total short interest was 3,200 shares in November as published by FINRA. Its up 23.08% from 2,600 shares, reported previously. With 36,900 shares average volume, it will take short sellers 0 days to cover their STLT’s short positions. About 6,343 shares traded hands. Spotlight Innovation Inc (OTCMKTS:STLT) has risen 38.20% since April 14, 2016 and is uptrending. It has outperformed by 33.51% the S&P500.

Spotlight Innovation Inc., formerly American Exploration Corporation, is a bioscience company. The company has a market cap of $13.25 million. The Firm is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. It currently has negative earnings. The Firm is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates.

STLT Company Profile

Spotlight Innovation Inc., formerly American Exploration Corporation, incorporated on May 11, 2006, is a bioscience company. The Firm is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. The Firm is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates. The Firm seeks to commercialize, for each technology candidate, one or more indications through sale, out-license and strategic relationships/marketing agreements, while continuing to retain, where practical, rights/field of use to other indications for commercialization. The Firm focuses on diseases that are rare, which are known as orphan diseases, or new or common but underserved, such as feline chronic kidney disease. As of December 31, 2015, the Company had three subsidiaries: Celtic Biotech Iowa, Inc., CDT Veterinary Therapeutics, Inc. (CDT) and Memcine Pharmaceuticals, Inc.

More notable recent Spotlight Innovation Inc (OTCMKTS:STLT) news were published by: Prnewswire.com which released: “Spotlight Innovation Inc. Issues Statement About Recent Stock Trading Activity” on November 09, 2016, also Prnewswire.com with their article: “Spotlight Innovation Appoints Cassandra K. MacArthur as Senior Vice President …” published on September 01, 2016, Prnewswire.com published: “Spotlight Innovation Inc. Joins Battle Against Zika Virus” on August 29, 2016. More interesting news about Spotlight Innovation Inc (OTCMKTS:STLT) were released by: Prnewswire.com and their article: “Spotlight Innovation Subsidiary Celtic Biotech Iowa Receives Approval to …” published on November 10, 2016 as well as Prnewswire.com‘s news article titled: “Spotlight Innovation Expands Its Patent Estate of Snake Venom-Derived Therapeutics” with publication date: November 04, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Peter Erickson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>